UT Austin-founded Kyn Therapeutics has been backed by Celgene in a strategic pact that also includes a $80m non-equity payment, giving Celgene the right to license two programs.

Kyn Therapeutics, a US-based developer of immunometabolic cancer drugs spun out from University of Texas (UT) at Austin, today secured funding from pharmaceutical company Celgene as part of a strategic partnership.
Founded in 2016, Kyn Therapeutics is working on cancer drugs that will target interactions between organism-sustaining metabolic processes and the immune system, a group of biological functions known as the immunometabolism.
The spinout was co-founded by George Georgiou, a professor and the Laura Jennings Turner chair in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?